Protective efficacy of a candidate live attenuated vaccine derived from the SD-R strain of lineage 1 porcine reproductive and respiratory syndrome virus against a lethal challenge with HP-PRRSV HuN4 in piglets

Microbiol Spectr. 2023 Dec 12;11(6):e0198423. doi: 10.1128/spectrum.01984-23. Epub 2023 Oct 11.

Abstract

Both highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) and NADC30-like PRRSV have caused tremendous economic losses to the Chinese pig industry. In this study, a good challenge model was established to evaluate the protection afforded by the candidate SD-R vaccine against infection with a representative HP-PRRSV strain (HuN4). The control piglets in the challenge experiment displayed obvious clinical symptoms of PRRSV infection, with a mortality rate up to 40%. In contrast, all the piglets in the vaccinated challenged group survived, and only some pigs had transient fever. The daily gain of SD-R immunized group piglets was significantly increased, and the pathological changes were significantly reduced. In addition, the viral replication levels in the serum of the immunized group were significantly lower than those of the challenged control group. The live attenuated vaccine SD-R strain can provide protection against HP-PRRSV challenge, indicating that the SD-R strain is a promising vaccine candidate for use in the swine industry.

Keywords: HP-PRRSV HuN4; SD-R; attenuated vaccine; cross-protection efficacy; lineage 1.

MeSH terms

  • Animals
  • Antibodies, Viral
  • Porcine Reproductive and Respiratory Syndrome* / prevention & control
  • Porcine respiratory and reproductive syndrome virus*
  • Swine
  • Vaccines, Attenuated
  • Viral Vaccines*

Substances

  • Vaccines, Attenuated
  • Viral Vaccines
  • Antibodies, Viral